Nagayama Manabu, Funayama Yohei, Taniguchi Osamu, Hatano Kaoru, Oguro Kunihiko, Owada Jun, Sakamoto Hirotsugu, Yano Tomonori, Longman Randy Scott, Yamamoto Hironori
Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Weill Cornell Medicine, Jill Roberts Institute for Research in IBD, New York, NY, USA.
Clin J Gastroenterol. 2024 Oct;17(5):910-914. doi: 10.1007/s12328-024-02022-w. Epub 2024 Jul 31.
Ulcerative colitis (UC), a subtype of inflammatory bowel disease, occasionally manifests with extraintestinal manifestations. We present a 51-year-old male with refractory UC and immune thrombocytopenia (ITP) resistant to conventional treatments. The introduction of biologics, ustekinumab or adalimumab, resulted in clinical remission of colitis and improvements in platelet count. This case underscores the efficacy of biologics in managing refractory UC associated with ITP, emphasizing their potential to control intestinal inflammation and address concurrent thrombocytopenia, potentially avoiding surgical intervention.
溃疡性结肠炎(UC)是炎症性肠病的一种亚型,偶尔会出现肠外表现。我们报告一例51岁男性,患有难治性UC和对传统治疗耐药的免疫性血小板减少症(ITP)。使用生物制剂乌司奴单抗或阿达木单抗后,结肠炎实现临床缓解,血小板计数有所改善。该病例强调了生物制剂在治疗与ITP相关的难治性UC中的疗效,突出了它们控制肠道炎症和解决并发血小板减少症的潜力,有可能避免手术干预。